GVB Biopharma Launches State-of-the-Art Isolation Facility with Over 300,000-Kilo Annual Production Capacity

PRINEVILLE, Ore., Feb. 18, 2025 /PRNewswire/ -- GVB Biopharma, the largest global producer of cannabinoids, is proud to announce the launch of its cutting-edge isolation facility, marking a significant leap in production capabilities and efficiency for the company. The new facility, developed over nearly two years of intensive planning and engineering, enables GVB Biopharma to meet the evolving demands of the global hemp and cannabinoid markets by delivering premium-quality isolates on an unprecedented scale.

"Our new isolation facility represents a major milestone for GVB Biopharma," said Drew Spiegel, CEO of GVB Biopharma. "We have designed this operation to ensure ultra-high throughput capacity while maintaining strict nutraceutical cGMP compliance. As a result, we're positioned to significantly increase production output and meet the rigorous standards required by our ever-expanding, sophisticated customer base."

"From day one, our focus has been on setting a new industry standard in both scale and precision," added Phil Swindells, COO of GVB Biopharma. "This cutting-edge facility underscores our commitment to delivering top-quality, high-volume cannabinoid isolates. We're excited to meet the evolving needs of our clients with this unprecedented level of production and consistency."

Unmatched Scale and Efficiency

The new facility has the capacity to produce over 300,000 kilograms of isolates per year, representing what the company believes to be the largest cannabis-specific operation of its kind globally. This elevated capacity positions GVB Biopharma to achieve up to $100 million in annual recurring revenue (ARR) while maintaining the highest level of product integrity and consistency. With significantly larger batch sizes and proprietary separation and refinement processes, the facility delivers higher-efficiency yields than ever before, ensuring GVB Biopharma remains at the forefront of cannabinoid production.

GVB Biopharma's proprietary methods and unique processes for isolation and refinement are key factors that distinguish it from competitors. These specialized techniques enable the company to achieve the highest levels of purity and consistency, reinforcing GVB Biopharma's industry-leading reputation.

Quality and Compliance

From the outset, every step of the facility's development focused on stringent compliance measures. The infrastructure supports nutraceutical cGMP standards to ensure product safety and quality. GVB Biopharma's commitment to robust quality controls and ongoing efforts toward additional certifications underscore the company's dedication to maintaining best-in-class manufacturing practices.

Positioning for Global Leadership

With the highest production capacity and quality standards on the market, GVB Biopharma is poised to serve an increasingly sophisticated global clientele. The company's expanded scale and focus on consistency, purity, and efficiency ensure that GVB Biopharma remains a trusted partner for brands and product manufacturers worldwide.

About GVB Biopharma

GVB Biopharma is the largest global producer of cannabinoids, offering end-to-end solutions for the hemp and cannabis industries. With a commitment to rigorous quality standards, cutting-edge research, and tailored product development, GVB Biopharma continues to drive innovation while meeting the highest benchmarks for safety, potency, and consistency.

For more information about GVB Biopharma and its full range of capabilities, please visit gvbbiopharma.com.

Media Contact:
Gabi de la Guardia
[email protected] 
(801) 203-0887

SOURCE GVB Biopharma